NEW YORK, Oct. 31, 2016 /PRNewswire/ -- Levi &
Korsinsky, LLP announces that it has commenced an investigation of
Trinity Biotech plc ("Trinity" or the "Company") (NASDAQ: TRIB)
concerning possible violations of federal securities laws by the
Company and/or certain of its officers and directors.
On October 4, 2016, Trinity
revealed that it was withdrawing its 510(k) premarket notification
submission for the Meritas Troponin-I Test and Meritas
Point-of-Care Analyzer, following the U.S. Food and Drug
Administration's advice. Trinity also said it would decrease its
spending by roughly 85%, to $1.5
million from $9 million each
year, and that it would close its Swedish facility, eliminating 40
jobs. Following this news, Trinity stock dropped $6.53 per share, more than 50 percent, to close
at $6.46 on October 4, 2016. To obtain additional information
about the investigation, go to:
http://zlk.9nl.com/trinity-biotech-trib
or contact Joseph E. Levi, Esq.
either via email at jlevi@zlk.com or by telephone at (212)
363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in
New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have
extensive expertise in prosecuting securities litigation involving
financial fraud, representing investors throughout the nation in
securities and shareholder lawsuits. Attorney advertising. Prior
results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY
10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
Logo -
http://photos.prnewswire.com/prnh/20120409/MM84375LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/shareholder-alert-levi--korsinsky-llp-announces-an-investigation-involving-possible-securities-fraud-violations-by-trinity-biotech-plc-and-certain-officers-and-directors----trib-300354238.html
SOURCE Levi & Korsinsky, LLP